BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 15583796)

  • 21. Molecular genetic alterations in endometrioid carcinomas of the ovary: similar frequency of beta-catenin abnormalities but lower rate of microsatellite instability and PTEN alterations than in uterine endometrioid carcinomas.
    Catasús L; Bussaglia E; Rodrguez I; Gallardo A; Pons C; Irving JA; Prat J
    Hum Pathol; 2004 Nov; 35(11):1360-8. PubMed ID: 15668893
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of TP53 immunohistochemistry on the histological grading system for endometrial endometrioid carcinoma.
    Yano M; Ito K; Yabuno A; Ogane N; Katoh T; Miyazawa M; Miyazawa M; Hasegawa K; Narahara H; Yasuda M
    Mod Pathol; 2019 Jul; 32(7):1023-1031. PubMed ID: 30742011
    [TBL] [Abstract][Full Text] [Related]  

  • 23. p53 overexpression and bcl-2 persistence in endometrial carcinoma: comparison of papillary serous and endometrioid subtypes.
    Zheng W; Cao P; Zheng M; Kramer EE; Godwin TA
    Gynecol Oncol; 1996 May; 61(2):167-74. PubMed ID: 8626128
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Histotype-genotype correlation in 36 high-grade endometrial carcinomas.
    Hoang LN; McConechy MK; Köbel M; Han G; Rouzbahman M; Davidson B; Irving J; Ali RH; Leung S; McAlpine JN; Oliva E; Nucci MR; Soslow RA; Huntsman DG; Gilks CB; Lee CH
    Am J Surg Pathol; 2013 Sep; 37(9):1421-32. PubMed ID: 24076778
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association of mammalian target of rapamycin with aggressive type II endometrial carcinomas and poor outcome: a potential target treatment.
    Peiró G; Peiró FM; Ortiz-Martínez F; Planelles M; Sánchez-Tejada L; Alenda C; Ceballos S; Sánchez-Payá J; Laforga JB
    Hum Pathol; 2013 Feb; 44(2):218-25. PubMed ID: 22955108
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular profile of grade 3 endometrioid endometrial carcinoma: is it a type I or type II endometrial carcinoma?
    Alvarez T; Miller E; Duska L; Oliva E
    Am J Surg Pathol; 2012 May; 36(5):753-61. PubMed ID: 22498825
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interpretation of p53 immunoreactivity in endometrial carcinoma: establishing a clinically relevant cut-off level.
    Alkushi A; Lim P; Coldman A; Huntsman D; Miller D; Gilks CB
    Int J Gynecol Pathol; 2004 Apr; 23(2):129-37. PubMed ID: 15084841
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Stepwise abnormality of sex steroid hormone receptors, tumor suppressor gene products (p53 and Rb), and cyclin E in uterine endometrioid carcinoma.
    Li SF; Shiozawa T; Nakayama K; Nikaido T; Fujii S
    Cancer; 1996 Jan; 77(2):321-9. PubMed ID: 8625241
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PTEN expression is associated with prognosis for patients with advanced endometrial carcinoma undergoing postoperative chemotherapy.
    Kanamori Y; Kigawa J; Itamochi H; Sultana H; Suzuki M; Ohwada M; Kamura T; Sugiyama T; Kikuchi Y; Kita T; Fujiwara K; Terakawa N
    Int J Cancer; 2002 Aug; 100(6):686-9. PubMed ID: 12209607
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diagnostic utility of phosphatase and tensin homolog, beta-catenin, and p53 for endometrial carcinoma by thin-layer endometrial preparations.
    Norimatsu Y; Miyamoto M; Kobayashi TK; Moriya T; Shimizu K; Yanoh K; Tsukayama C; Miyake Y; Ohno E
    Cancer; 2008 Jun; 114(3):155-64. PubMed ID: 18431720
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Correlation between NDRG1 and PTEN expression in endometrial carcinoma.
    Chen J; Li S; Yang Z; Lu G; Hu H
    Cancer Sci; 2008 Apr; 99(4):706-10. PubMed ID: 18377423
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Loss of heterozygosity on 10q23.3 and mutation of the tumor suppressor gene PTEN in benign endometrial cyst of the ovary: possible sequence progression from benign endometrial cyst to endometrioid carcinoma and clear cell carcinoma of the ovary.
    Sato N; Tsunoda H; Nishida M; Morishita Y; Takimoto Y; Kubo T; Noguchi M
    Cancer Res; 2000 Dec; 60(24):7052-6. PubMed ID: 11156411
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Expression of phosphatase and tensin homology deleted on chromosome ten(PTEN) and p53 protein and their significance in human hepatocellular carcinomas].
    Cheng LM; Wang SY; Lin JS
    Ai Zheng; 2003 Jan; 22(1):42-5. PubMed ID: 12561434
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PTEN expression in tamoxifen-associated endometrial cancers.
    Holtz D; Ramondetta LM; Burke TW; Palazzo JP; Dunton CJ; Atkinson EN; Broaddus RR
    Anticancer Res; 2002; 22(5):2945-8. PubMed ID: 12530022
    [TBL] [Abstract][Full Text] [Related]  

  • 35. L-type amino acid transporter 1 expression increases in well-differentiated but decreases in poorly differentiated endometrial endometrioid adenocarcinoma and shows an inverse correlation with p53 expression.
    Watanabe J; Yokoyama Y; Futagami M; Mizunuma H; Yoshioka H; Washiya K; Hana K; Endou H; Okayasu I
    Int J Gynecol Cancer; 2014 May; 24(4):659-63. PubMed ID: 24694899
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic significance of overexpression of p53 in uterine endometrioid adenocarcinomas with an analysis of nuclear grade.
    Urabe R; Hachisuga T; Kurita T; Kagami S; Kawagoe T; Matsuura Y; Shimajiri S
    J Obstet Gynaecol Res; 2014 Mar; 40(3):812-9. PubMed ID: 24246002
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PTEN mutations do not cause nuclear beta-catenin accumulation in endometrial carcinomas.
    Wappenschmidt B; Wardelmann E; Gehrig A; Schöndorf T; Maass N; Bonatz G; Gassel AM; Pietsch T; Mallmann P; Weber BH; Schmutzler RK
    Hum Pathol; 2004 Oct; 35(10):1260-5. PubMed ID: 15492994
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Expression and clinical significance of Beclin1 and PTEN in endometrial carcinoma].
    Zhao JH; Wan XY; Xie X; Zhou CY; Wu QY
    Ai Zheng; 2006 Jun; 25(6):753-7. PubMed ID: 16764775
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expression of PTEN in endometrial liquid-based cytology.
    Di Lorito A; Zappacosta R; Capanna S; Gatta DM; Rosini S; Schmitt FC
    Acta Cytol; 2014; 58(5):495-500. PubMed ID: 25358681
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Loss of PTEN expression is associated with metastatic disease in patients with endometrial carcinoma.
    Salvesen HB; Stefansson I; Kalvenes MB; Das S; Akslen LA
    Cancer; 2002 Apr; 94(8):2185-91. PubMed ID: 12001116
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.